Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-06-30
Johnson Philip L Files Jazz Pharmaceuticals plc (JAZZ) Form 4 - June 30, 2026
Johnson Philip L sold 3.3K JAZZ shares worth $794.7K in this Form 4 filing, reported to the SEC on 2026-06-30.
- Insider
- Johnson Philip L
- Issuer
- Jazz Pharmaceuticals plc JAZZ · NASDAQ
- Filed
- Period
- 2026-06-30
- Accession
- 0002013156-26-000007
- Source
- Official filing on sec.gov ↗
Transactions (1)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Johnson Philip L | 2026-06-30 | Sell | 3.3K | $237.72 | $794.7K | Direct |
| Net change | −3.3K | −$794.7K | ||||
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Track JAZZ insider activity
Get alerted when Jazz Pharmaceuticals plc executives buy or sell their shares.